All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): BX003
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: BX003
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 16, 2020
Details:
Presentation featured at The Liver Meeting® 2020, the AASLD Annual Meeting, details support for the design of phage therapy candidate BX003, an orally delivered candidate phage therapy targeting Klebsiella pneumoniae for the treatment of both IBD and PSC.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): BX002
Therapeutic Area: Gastroenterology Product Name: BX002
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 03, 2020
Details:
The first-in-human study is designed to evaluate the safety, pharmacokinetics, and ability of orally-administered BX002 to deliver viable phage to the gut.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): BX002
Therapeutic Area: Gastroenterology Product Name: BX002
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 21, 2020
Details:
The poster presentation details a phage therapy panel, comprised of phage directed against Klebsiella pneumoniae, showing a broad target host range and the potential to address carbapenem-resistant and extended spectrum beta-lactamase (ESBL)-producing bacteria.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): BX001
Therapeutic Area: Dermatology Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 20, 2020
Details:
BiomX is developing BX001, its lead product candidate, to modify the appearance of acne prone skin.